Meet the Team

We are on a mission to change the way in which healthcare is provided by giving researchers the ability to closely examine the continuum from health to disease. In order to make this vision a reality, we brought together the most experienced management team, renowned scientists, industry leading investors and expert advisors, to form a collaborative ecosystem, united through the common goal of advancing the science of precision health.

Kevin Hrusovsky

Chairman, Chief Executive Officer, President

Kevin Hrusovsky is an American biotech entrepreneur, engineer, and healthcare visionary who has dedicated his 30-year career to transforming medicine from reactive “sick care” to preventative and personalized healthcare.

Hrusovsky is leading the charge to establish a new paradigm for healthy living based on peer-reviewed science that addresses the continuum from health to disease at the molecular structure level in the human body. He catalyzed a precision health movement that began in 2008 with the launch of the Revolutionaries for Global Health Summit Series to promote innovation for eradicating disease and personalizing global health. In 2016, Hrusovsky founded Powering Precision Health, the annual summit that quickly become the industry’s leading platform and premier forum for advancing the deep science that powers precision health.

An acclaimed life sciences and healthcare authority, Hrusovsky is regularly asked to provide both in-depth analysis and the big picture view on achieving industry-wide transformation to true precision medicine. He has been a featured guest on numerous media outlets, including ABC’s Good Morning America, CBS, NBC, CNN, CNBC, NPR Science Friday, USA Today, Forbes, Fortune, Bloomberg, Wall Street Journal, New York Times, International Business Times, Washington Post, STAT, Quartz, HuffPost, The Guardian, Scientific American, Boston Globe, Wired, and Fast Company.

Hrusovsky has been recognized with many awards and accolades, including a 2017 BBJ Innovation All-Star award for transforming the practices of medicine and health. He is a three-time Award Finalist of the EY Entrepreneur of the Year® (2007, 2017 and 2018) and received the Lifetime Achievement Award for Leadership (2018) and E.G. Bailey Entrepreneurship Award (2013), both from The Ohio State University. In 2015, Hrusovsky was named a BostInno’s 50 on Fire Awards Finalist in Healthcare and Medicine.

A coveted thought leader and dynamic speaker, Hrusovsky is regularly invited to keynote and participate at leading conferences, executive summits and panel discussions, including the BIO International Convention, J.P. Morgan Healthcare Conference, One Mind Summit, Konkussion Retreat, PULSE: The Atlantic Summit on Health Care, MedCity CONVERGE, Next Generation Dx Summit, the annual conference of the Personalized Medicine Coalition, and World Innovation Forum.

He currently serves as President, Chairman and CEO of Quanterix, a company digitizing biomarker analysis to advance the science of precision health. In 2017, he took Quanterix public in one of the most successful IPOs for a life science tools company in recent history. Under his leadership, the company acquired Aushon and regained all rights and privileges associated with its groundbreaking Simoa technology through the termination of a license agreement with bioMérieux

Prior to joining Quanterix, he was President of Life Sciences and Technologies at PerkinElmer, CEO of Caliper Life Sciences (now PerkinElmer), and CEO of Zymark Corporation (now PerkinElmer). Previously, he served as President of FMC Corporation’s Pharmaceuticals and head of International Agricultural Products and held key management positions at E.I. DuPont de Nemours.

Hrusovsky is renowned for his strong track record of launching disruptive technologies, building fast-growing companies, and developing successful commercialization strategies. He lends his business expertise on the boards of innovative technology companies including BioreclamationIVT, Caliper Life Sciences, Cell Signaling Technology, 908 Devices, Cellaria, SeraCare, Synap Dx, Xenogen and Solect Energy. Hrusovsky is committed to education and serves on the Educational Board of the Massachusetts Biotech Council, the Advisory Committee for the Center for Biomedical Engineering at Brown University, the Association for Laboratory Automation, the JALA Editorial Board, and the Strategy Committee of Children’s Hospital Boston.

Hrusovsky holds an M.B.A. from Ohio University and a B.S. in Mechanical Engineering from The Ohio State University. He received an Honorary Doctorate from Framingham State University for his vast contributions in life sciences and personal medicine. In addition, he helped build competitive strategy curriculum at the Institute for Strategy & Competitiveness at Harvard Business School. Follow Kevin Hrusovsky on Twitter @KevinHrusovsky and LinkedIn @KevinHrusovsky.

William Geist

Chief Operating Officer

Will Geist has served as Chief Operating Officer from Quanterix since November 2020. Will is a proven, innovative, entrepreneur with a mission focused on improving the human condition through the power of science. With more than 25 years of experience, Will has an exceptional track record of developing and executing strategies that drive growth and fuel innovation. Having long admired Quanterix and the precision health movement, joining the team as the COO is a natural extension of Will’s life-time work. Prior to Quanterix, Will served as the Vice President and General Manager for two of Thermo Fisher Scientific’s largest business units; Protein and Cell Analysis (PCA) and qPCR. During this time, his teams developed and commercialized products across a broad range of proteomic and genomic technologies for research and clinical applications. He also served a key leadership role in Thermo Fisher Scientific’s Biosciences Division COVID-19 Task Force. Prior to Thermo Fisher, will held leadership roles with increasing responsibility at QIAGEN (Quanta BioSciences), Affymetrix, and Life Technologies. He holds a B.A. in Biology from Dartmouth College.

Amol Chaubal

Chief Financial Officer

Mr. Amol Chaubal joined Quanterix in 2019 from global medical technology company Smith & Nephew, where he was the CFO of Global Operations. Prior to his time at Smith & Nephew, he served as Corporate Vice-President and Head of Finance for PAREXEL’s CRS business from June 2015 to October 2017. Between May 2013 and May 2015, he was the North America CFO and later Regional COO at Brookfield Renewable Energy Group, which is part of Brookfield Asset Management. Prior to Brookfield, Amol was CFO North America at Novartis Vaccines & Diagnostic and had spent 11 years with Novartis in positions of increasing responsibility across Switzerland, Canada, and the United States. He has an MBA (with distinction) from INSEAD (France). He began his career with Procter & Gamble, after completing Masters degree in Chemical Engineering from Indian Institute of Technology, Mumbai.

David Duffy, PhD

Vice President, Research and Chief Technology Officer

David joined Quanterix in 2007 and leads the team of scientists developing its single-molecule detection technology.
He is an inventor on 12 U.S. patents and has more than 20 publications in the fields of surface chemistry, microfluidics, and bioanalysis. He was previously at Surface Logix, where he was the Director of Pharmacomer Technology. There David oversaw the development of a novel chemical technology that resulted in two drug candidates currently in Phase II clinical trials. Prior to that, David was at Gamera Biosciences where he was a co-inventor of a centrifugal microfluidic that was acquired and commercialized by Tecan. He was a postdoctoral research fellow in the Department of Chemistry and Chemical Biology at Harvard University. David was the first Sir Alan Wilson Research Fellow of Emmanuel College, University of Cambridge, and holds a Ph.D. in Physical Chemistry from the Department of Chemistry at the University of Cambridge.

Mark Roskey, PhD

Senior Vice President, Commercial & Assays

Mark joined Quanterix in mid 2014 as the Vice President and General Manager of Applications and Reagents. He has more than 25 years of experience in the life science industry focusing on product R&D, applications development, strategic sales and marketing, and overall business management for complex biological solutions and automated instrument systems. He comes to Quanterix from PerkinElmer’s LST division where he was VP/GM of the America’s Sales and Service organization. Prior to PerkinElmer, Mark held senior level commercial and technical positions at Caliper Life Sciences, which was acquired by PerkinElmer in 2011. Mark holds a Ph.D. in Microbiology from the University of Notre Dame and completed a postdoctoral fellowship in Molecular Immunobiology at the Harvard Medical School.

Dawn R. Mattoon, PhD

Senior Vice President, Research Products

Dawn joined Quanterix in February of 2018 as Senior Vice President of Research Products. Dawn brings a strong breadth of experience in the life science industry and has held a number of leadership positions in R&D, Strategy, and General Management for companies including Invitrogen, Life Technologies, Thermo Fisher, and Cell Signaling Technologies. During this time, she developed and commercialized products across a range of proteomic and genomic technologies including protein microarrays, quantum dots, next-generation sequencing, laser capture microdissection, antibodies, and immunoassays. Dawn has also served on global leadership teams focused on mentoring and developing female leaders. Most recently, Dawn served as the Vice President for Product Development at Cell Signaling Technologies, a leading antibody provider. Dawn completed both her Ph.D. and postdoctoral work at Yale University, studying tyrosine kinase signaling pathways.

Mary Ellen Cortizas, JD

Vice President, CRO and Laboratory Services

Mary Ellen developed her operational expertise over a 30-year career at Boston Children’s Hospital. As Administrative Director of the Department of Laboratory Medicine, Mary Ellen had operational responsibility for clinical chemistry, hematology, microbiology, blood bank and molecular diagnostics. In addition to laboratory roles, Mary Ellen had active roles in enterprise-wide information technology, quality and regulatory management, emergency management, and strategic planning.

Prior to joining Quanterix, Mary Ellen was a founder and Chief Operating Officer at Claritas Genomics, a molecular genomics company dedicated to advancing precision care for pediatric rare disease. Claritas became the first clinical molecular diagnostic laboratory to achieve both ISO 15189 and New York State licensure for its unique exome-based diagnostics. Mary Ellen oversaw successful execution of a $9 million grant to sequence 20,000 exomes for the Veteran Adminstration’s Million Veterans project.

Mary Ellen has served on American Society of Clinical Pathologist Board of Registry exam committees, and is currently on the boards of two not-for-profit organizations focused on youth development.

Mary Ellen graduated from Suffolk Law School and holds a BA in Biology from Tufts University.

Denise Chittick

Chief Human Resources Officer

Denise joined Quanterix in January of 2021 as the Chief Human Resources Officer. She has over 25 years of experience bringing innovative human resources strategies to rapidly scaling international organizations in the medical device, consumer goods and SaaS industries. Most recently, she was the CHRO/VP of Human Resources for Reflexis Systems until it was acquired. Denise’s experience also includes global human resources leadership roles in several organizations where, among other things, she led projects encompassing acquisition integration, change management and organizational design. Denise holds a B.A. in Psychology from the University of Delaware, an M.A. in Psychology from Fairfield University and an M.B.A. from the University of Rhode Island.

Brian Keane, JD

Senior Vice President and Senior Legal Counsel

Brian Keane brings over 20 years of experience advising the management and boards of life sciences companies to his role as Vice President, Senior Legal Counsel of Quanterix. Prior to joining Quanterix, he was a Corporate & Securities Partner in the Life Sciences Practice at Mintz Levin. While at Mintz Levin, Mr. Keane served as outside counsel to dozens of life science companies, advising such clients on corporate governance, risk mitigation, SEC disclosure and compliance, financing transactions, M&A and strategic transactions, product development and commercialization and other matters. Mr. Keane holds a BS in electrical engineering from Tufts University and received his law degree from Boston College Law School.

John Fry, JD

General Counsel and Corporate Secretary

John joined Quanterix in 2019 and has over 25 years of experience as an attorney in the medical and technology industries. He previously served for over 10 years as Senior Vice President, General Counsel and Secretary of Analogic Corporation, a global supplier of medical and aviation security technology. Prior to joining Analogic, John was a principal in the law firm of Driggs, Hogg & Fry Co. L.P.A., where his practice focused primarily on technology and intellectual property law. He previously held various positions of increasing responsibility at Philips Medical Systems, including Senior Corporate Counsel and Intellectual Property Manager and counsel to Philips’ global computed tomography business. John began his career as an electrical engineer and engineering manager and is a named inventor on 10 U.S. patents. He holds bachelor’s and master’s degrees in electrical engineering from Case Western Reserve University and a law degree from Cleveland-Marshall College of Law.

Kevin Hrusovsky

Chairman, Chief Executive Officer, President

Kevin Hrusovsky is an American biotech entrepreneur, engineer, and healthcare visionary who has dedicated his 30-year career to transforming medicine from reactive “sick care” to preventative and personalized healthcare.

Hrusovsky is leading the charge to establish a new paradigm for healthy living based on peer-reviewed science that addresses the continuum from health to disease at the molecular structure level in the human body. He catalyzed a precision health movement that began in 2008 with the launch of the Revolutionaries for Global Health Summit Series to promote innovation for eradicating disease and personalizing global health. In 2016, Hrusovsky founded Powering Precision Health, the annual summit that quickly become the industry’s leading platform and premier forum for advancing the deep science that powers precision health.

An acclaimed life sciences and healthcare authority, Hrusovsky is regularly asked to provide both in-depth analysis and the big picture view on achieving industry-wide transformation to true precision medicine. He has been a featured guest on numerous media outlets, including ABC’s Good Morning America, CBS, NBC, CNN, CNBC, NPR Science Friday, USA Today, Forbes, Fortune, Bloomberg, Wall Street Journal, New York Times, International Business Times, Washington Post, STAT, Quartz, HuffPost, The Guardian, Scientific American, Boston Globe, Wired, and Fast Company.

Hrusovsky has been recognized with many awards and accolades, including a 2017 BBJ Innovation All-Star award for transforming the practices of medicine and health. He is a three-time Award Finalist of the EY Entrepreneur of the Year® (2007, 2017 and 2018) and received the Lifetime Achievement Award for Leadership (2018) and E.G. Bailey Entrepreneurship Award (2013), both from The Ohio State University. In 2015, Hrusovsky was named a BostInno’s 50 on Fire Awards Finalist in Healthcare and Medicine.

A coveted thought leader and dynamic speaker, Hrusovsky is regularly invited to keynote and participate at leading conferences, executive summits and panel discussions, including the BIO International Convention, J.P. Morgan Healthcare Conference, One Mind Summit, Konkussion Retreat, PULSE: The Atlantic Summit on Health Care, MedCity CONVERGE, Next Generation Dx Summit, the annual conference of the Personalized Medicine Coalition, and World Innovation Forum.

He currently serves as President, Chairman and CEO of Quanterix, a company digitizing biomarker analysis to advance the science of precision health. In 2017, he took Quanterix public in one of the most successful IPOs for a life science tools company in recent history. Under his leadership, the company acquired Aushon and regained all rights and privileges associated with its groundbreaking Simoa technology through the termination of a license agreement with bioMérieux

Prior to joining Quanterix, he was President of Life Sciences and Technologies at PerkinElmer, CEO of Caliper Life Sciences (now PerkinElmer), and CEO of Zymark Corporation (now PerkinElmer). Previously, he served as President of FMC Corporation’s Pharmaceuticals and head of International Agricultural Products and held key management positions at E.I. DuPont de Nemours.

Hrusovsky is renowned for his strong track record of launching disruptive technologies, building fast-growing companies, and developing successful commercialization strategies. He lends his business expertise on the boards of innovative technology companies including BioreclamationIVT, Caliper Life Sciences, Cell Signaling Technology, 908 Devices, Cellaria, SeraCare, Synap Dx, Xenogen and Solect Energy. Hrusovsky is committed to education and serves on the Educational Board of the Massachusetts Biotech Council, the Advisory Committee for the Center for Biomedical Engineering at Brown University, the Association for Laboratory Automation, the JALA Editorial Board, and the Strategy Committee of Children’s Hospital Boston.

Hrusovsky holds an M.B.A. from Ohio University and a B.S. in Mechanical Engineering from The Ohio State University. He received an Honorary Doctorate from Framingham State University for his vast contributions in life sciences and personal medicine. In addition, he helped build competitive strategy curriculum at the Institute for Strategy & Competitiveness at Harvard Business School. Follow Kevin Hrusovsky on Twitter @KevinHrusovsky and LinkedIn @KevinHrusovsky.

Martin Madaus, PhD

Chairman and Chief Executive Officer, Ortho Clinical Diagnostics

Martin brings more than 20 years of experience in the diagnostics and life science industries. He most recently served as President, Chairman and CEO of Millipore Corporation, recently acquired by Merck KGaA. Before joining Millipore, Dr. Madaus was President, CEO and head of North American Operations for Roche Diagnostics Corporation. Prior to this he served as Vice President of Business Development for Roche Molecular Diagnostics and General Manager of Boehringer Mannheim Canada. He also held a number of senior-level sales, marketing and product management positions with Boehringer Mannheim Corporation in both Germany and the US. Martin is a director of the Massachusetts High Technology Council and serves on the Life Sciences Collaborative Leadership Council of the Massachusetts Technology Collaborative. He holds a Doctor of Veterinary Medicine from the University of Munich, Germany and a Ph.D. in Veterinary Medicine from the Veterinary School of Hanover, Germany.

Keith L. Crandell

Co-Founder & Managing Director, ARCH Venture Partners

Keith Crandell is a co-founder and a Managing Director of ARCH Venture Partners. He focuses on chemical and specialty materials companies, electronics and instrumentation, optics and photonics, communications, and enterprise infrastructure businesses. He previously served as Senior Manager at ARCH Development Corporation, where he was responsible for ARCH Venture Fund I activities at Argonne National Laboratory. Keith has played a key role in the formation and initial funding round of Quanterix, Alfalight, PixelEXX Systems, ALIS Corp., Eichrom Industries, Nanophase Technologies, and Illinois Superconductor. He serves on the board of Quanterix, Nanosys, Alfalight, Adesto Technologies, Boreal Genomics, PixelEXX Systems, Univa, and Ciespace, and also as a director of the Illinois Venture Capital Association. Keith holds an M.B.A. from The University of Chicago, an M.S. in Chemistry from the University of Texas at Arlington, and a B.S. in Chemistry and Mathematics from St. Lawrence University.

David Walt, PhD

Senior Investigator, Brigham and Women’s Hospital, Department of Pathology, Core Faculty Member-Wyss Institute, Harvard Medical School at Harvard University

David R. Walt is a member of the faculty at Harvard Medical School in the Department of Pathology at Brigham and Women’s Hospital, is a Member of the Wyss Institute at Harvard University and is a Howard Hughes Medical Institute Professor. Previously, he was University Professor at Tufts University. Dr. Walt is the Scientific Founder of Quanterix Corp and has co-founded several other life sciences startups including Illumina Inc., Ultivue, Inc. and Arbor Biotechnologies. He has received numerous national and international awards and honors for his fundamental and applied work in the field of optical microwell arrays and single molecules. He is a member of the National Academy of Engineering, the National Academy of Medicine, a Fellow of the American Academy of Arts and Sciences, a Fellow of the American Institute for Medical and Biological Engineering, and a Fellow of the National Academy of Inventors. He has published over 300 papers and holds nearly 100 patents. He received a B.S. in chemistry from the University of Michigan and a Ph.D. in chemical biology from SUNY at Stony Brook, and did postdoctoral studies at MIT.

Paul Meister

Co-founder, Liberty Lane Partners, LLC

Paul is co-founder of Liberty Lane Partners, LLC, a private investment company with diverse investments in healthcare and distribution-related industries. He is also Chairman and Chief Executive Officer of inVentiv Health. Paul previously served as Chairman of the Board of Thermo Fisher Scientific Inc. and Vice Chairman of Fisher Scientific International, Inc. prior to Fisher’s merger with Thermo. During his tenure as an executive officer of Fisher Scientific, the company’s revenue and operating income grew at a compound annual growth rate of 15% and 23% respectively, as operations grew from two countries to 27, and sales expanded into 140 countries worldwide. He is a director of LKQ Corporation, Scientific Games Corporation, co-chair of the University of Michigan’s Life Sciences Institute External Advisory Board and serves on the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University. Paul holds an M.B.A. from Northwestern University.

Marijn Dekkers

Chairman of Novalis LifeSciences

Marijn E. Dekkers is founder and chairman of Novalis LifeSciences LLC, an investment and advisory firm for the Life Science industry that he founded in 2017. From 2010-2016, Dr. Dekkers served as CEO of Bayer AG in Leverkusen, Germany. From 2002-2009, he was CEO of Thermo Fisher Scientific in Waltham, MA, USA. He started his career in 1985 as a research scientist at General Electric’s Corporate R&D Center in Niskayuna, NY, USA. Dr. Dekkers received his PhD and M.S. in Chemical Engineering from the University of Eindhoven and his B.S in chemistry from the Radboud University, both in the Netherlands. He holds dual U.S. and Dutch citizenship.

Sarah Hlavinka

Senior Vice President and General Counsel, Itron

Hlavinka brings to the Quanterix Board more than 25 years of experience as a senior advisor and business executive growing and scaling a variety of enterprises in the IT, service, manufacturing and healthcare industries. She currently serves as senior vice president and general counsel at Itron (NASDAQ: ITRI), which enablesutilities and cities to safely, securely and reliably deliver critical infrastructure services to communities in more than 100 countries. Prior to Itron, Hlavinka served as executive vice president, general counsel and secretary at Xerox Corporation. Previously, she has served in various corporate legal roles in companies including Fisher Scientific International, Benchmark Electronics, Hewlett Packard Company and Cooper Industries. Hlavinka earned her B.A. in history, Spanish minor from Texas A&M University and received her law degree from the University of Texas School of Law.

Ready to take your biomarker research to the next level?

request a quote